key: cord-0017156-3e0ba677 authors: Stahl, Klaus; Schenk, Heiko; Kühn, Christian; Wiesner, Olaf; Hoeper, Marius M.; David, Sascha title: Extracorporeal membrane oxygenation in non-intubated immunocompromised patients date: 2021-04-30 journal: Crit Care DOI: 10.1186/s13054-021-03584-8 sha: 3d4d50d3e7a93bbed9650b25166eb9a724eb4316 doc_id: 17156 cord_uid: 3e0ba677 nan Veno-venous (VV) extracorporeal membrane oxygenation (ECMO) has become an integral part in the rescue therapy of severe acute respiratory distress syndrome (ARDS) and may be lifesaving in patients with refractory hypoxemia [1] . Ventilator-induced lung injury, ventilatoracquired pneumonia and ventilator-induced diaphragm dysfunction are severe side effects of invasive ventilation and may contribute to the complex pathophysiology of multi-organ failure and death in ARDS [2] . The use of ECMO in patients who are awake and spontaneously breathing (termed awake ECMO) might avoid side effects and complications associated with sedation, intubation and invasive mechanical ventilation [3] . Our group reported the first successful use of awake ECMO in six ARDS patients several years ago [4] . We then concluded that the concept of an awake ECMO strategy as a potential alternative to intubation deserves further evaluation especially in patients with higher mortality following traditional invasive ventilation and ECMO support. In immunocompromised patients with ARDS who require ECMO support, the 6-month mortality exceeds 70% with a reported in-hospital mortality of 81% in patients following hematopoietic stem cell transplantation (HSCT) [5] . In immunocompromised patients with Pneumocystis jirovecii-associated pneumonia and severe ARDS we demonstrated earlier that a primarily awake ECMO strategy seems to be a promising strategy [6] . We therefore hypothesized that awake ECMO support to avoid invasive ventilation in selected immunocompromised patients might yield improved outcomes. Here, we present a comprehensive summary of 18 immunocompromised patients who received awake ECMO support for management of ARDS at our institution between 09/2012 and 09/2020. The patient characteristics are shown in Table 1 . At inclusion, the majority of patients had isolated lung failure indicated by rather low rates of low-dose vasopressor support (28%) and renal replacement therapy (6%) as well as physiological serum lactate concentrations. Median (Interquartile Range (IQR)) oxygenation indices at ECMO initiation were 72 (65-82) mmHg with normal values for pH and pCO 2 despite maximal respiratory support by noninvasive ventilation (NIV). ECMO was initiated after a median of 1 (1-3) days following initial ICU admission and was carried out for 11 (9-18) days. Eleven patients (61%) required secondary intubation after a median of 4 (2-6) days. The most common cause for secondary intubation was agitation (6/11, 55%) stressing the critical role for delirium preventive strategies in these patients. The majority (4/6) of patients with agitation as primary cause for failing awake ECMO support developed agitation without any prior respiratory or circulatory deterioration. The choice of anxiolytic medication showed a trend toward a more frequent use of benzodiazepines in patients with agitation compared to all other patients (6/6 vs. 4/12), while low-dose morphine was used less frequently (2/6 vs. 7/12). *Correspondence: stahl.klaus@mh-hannover.de † Klaus Stahl and Heiko Schenk have contributed equally to the manuscript and are both considered first authors 1 Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany Full list of author information is available at the end of the article 28-day-, in hospital-and 6-month mortality rates were 44% (8/18), 50% (9/18) and 50%, respectively. In-hospital mortality was 29% (2/7) in solid organ transplantation patients and 50% (3/6) in hemopoietic stem cell transplantation patients. In-hospital mortality was 73% in patients who required secondary intubation and 14% in patients who did not require intubation while on ECMO support (p = 0.023, Hazard Ratio: 0.133 (0.058-0.789)). Description of the patient cohort (n = 18) that received awake ECMO support. All immunocompromised patients with severe ARDS were non-systematically screened by two ECMO experienced ICU attending intensivists for the possibility of an awake ECMO strategy following inclusion and exclusion criteria that have been previously defined by our group as part of the study describing first use of awake ECMO in ARDS patients (4) (NCT01669863). In general, the exclusion criteria stressed the absence of septic or cardiogenic shock and multi-organ failure An exploratory analysis suggested several factor associated with later failure of an awake ECMO concept ( Table 2) . Although this study, to the best of our knowledge, represents the largest experience with awake ECMO in ARDS patients, conclusions are still limited by its small sample size and the uncontrolled nature. Despite these limitations, our findings support the notion that an awake ECMO strategy might be a viable treatment option for immunocompromised patients with severe ARDS, especially in those patients without overt multi-organ failure. Further studies are required to determine the possible role of the awake ECMO concept in patients with ARDS. ECMO for severe ARDS: systematic review and individual patient data metaanalysis Mechanical power during extracorporeal membrane oxygenation and hospital mortality in patients with acute respiratory distress syndrome Awake" extracorporeal membrane oxygenation (ECMO): pathophysiology, technical considerations, and clinical pioneering Extracorporeal membrane oxygenation instead of invasive mechanical ventilation in patients with acute respiratory distress syndrome Six-month outcome of immunocompromised severe ARDS patients rescued by ECMO. An international multicenter retrospective study Better be awake"-a role for awake extracorporeal membrane oxygenation in acute respiratory distress syndrome due to Pneumocystis pneumonia Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations Not applicable.